{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:57Z","timestamp":1787017137781,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"crossref","award":["R-995882"],"award-info":[{"award-number":["R-995882"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"crossref","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Professor Nanna Svartz","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["FAI-2023-1055"],"award-info":[{"award-number":["FAI-2023-1055"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1000881"],"award-info":[{"award-number":["OLL-1000881"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ulla and Roland Gustafsson Foundation","award":["2024-43"],"award-info":[{"award-number":["2024-43"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine belimumab efficacy assessed using the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) in patients with systemic lupus erythematosus (SLE) from phase III belimumab randomised controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post hoc analysis was carried out on five RCTs in active adult SLE: four with intravenous (BLISS-52, BLISS-76, BLISS-NEA, EMBRACE) and one with subcutaneous belimumab (BLISS-SC). The 52-week landmark assessments were analysed across trials. Treatment response was defined according to BICLA criteria (BILAG improvement; no worsening of disease activity based on BILAG and Systemic Lupus Erythematosus Disease Activity Index-2K; no deterioration in Physician\u2019s Global Assessment \u22650.3 (scale: 0\u20133); no treatment failure).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3086 patients received belimumab (n=1869) or placebo (n=1217). BICLA response frequencies at week 52 were greater with belimumab vs placebo in BLISS-52 (OR (95% CI): 1.49 (1.05\u20132.12); p=0.024), BLISS-NEA (1.62 (1.12\u20132.33); p=0.010) and BLISS-SC (1.89 (1.39\u20132.57); p&lt;0.001). A highly significant difference was observed in the pooled population (1.47 (1.25\u20131.72); p&lt;0.001; adjusted for trial variance). Belimumab yielded greater BICLA response frequencies than placebo irrespective of baseline glucocorticoid dose (&gt;7.5 or \u22647.5 mg\/day of a prednisone equivalent), in patients with baseline SLEDAI-2K\u226510 and in patients with positive anti-double-stranded (ds)DNA and\/or low C3\/C4 levels at baseline. Belimumab combined with anti-malarials yielded greater frequency of BICLA response attainment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis of five RCTs evaluating belimumab in SLE, belimumab conferred superiority over placebo to yield BICLA response in the overall study population and in subgroups of patients with high global or serological activity at baseline. The benefit of belimumab was more prominent when combined with anti-malarials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005444","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:50:15Z","timestamp":1745452215000},"page":"e005444","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nursen","family":"Cetrez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent\u2019s Hospital Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, The University of Melbourne at St Vincent\u2019s Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Ala","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric","family":"Morand","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Levitsky","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[{"name":"School of Public Health and Sydney MSK Research Flagship Centre, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025090312514956000_11.2.e005444.1","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med"},{"key":"2025090312514956000_11.2.e005444.2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.651249","article-title":"Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090312514956000_11.2.e005444.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2025090312514956000_11.2.e005444.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519"},{"key":"2025090312514956000_11.2.e005444.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025090312514956000_11.2.e005444.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac185"},{"key":"2025090312514956000_11.2.e005444.7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514956000_11.2.e005444.8","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090312514956000_11.2.e005444.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"2025090312514956000_11.2.e005444.10","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"key":"2025090312514956000_11.2.e005444.11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2020.1775928","article-title":"Which is the best SLE activity index for clinical trials?","volume":"31","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025090312514956000_11.2.e005444.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa383"},{"key":"2025090312514956000_11.2.e005444.13","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090312514956000_11.2.e005444.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.24698"},{"key":"2025090312514956000_11.2.e005444.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202760"},{"key":"2025090312514956000_11.2.e005444.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"2025090312514956000_11.2.e005444.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2025090312514956000_11.2.e005444.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025090312514956000_11.2.e005444.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025090312514956000_11.2.e005444.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2025090312514956000_11.2.e005444.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.41900"},{"key":"2025090312514956000_11.2.e005444.22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514956000_11.2.e005444.23","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025090312514956000_11.2.e005444.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214427"},{"key":"2025090312514956000_11.2.e005444.25","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2665-9913(19)30049-9","article-title":"Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials","volume":"1","author":"Parodis","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025090312514956000_11.2.e005444.26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41778","article-title":"What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials","volume":"73","author":"Furie","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514956000_11.2.e005444.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120886"},{"key":"2025090312514956000_11.2.e005444.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2025090312514956000_11.2.e005444.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"2025090312514956000_11.2.e005444.30","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2665-9913(21)00119-3","article-title":"Clinician-reported outcome measures in lupus trials: a problem worth solving","volume":"3","author":"Connelly","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090312514956000_11.2.e005444.31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090312514956000_11.2.e005444.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev387"},{"key":"2025090312514956000_11.2.e005444.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025090312514956000_11.2.e005444.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200937"},{"key":"2025090312514956000_11.2.e005444.35","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514956000_11.2.e005444.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025090312514956000_11.2.e005444.37","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/rheumatology\/keab080","article-title":"EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus","volume":"60","author":"Lindblom","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514956000_11.2.e005444.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead253"},{"key":"2025090312514956000_11.2.e005444.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216367"},{"key":"2025090312514956000_11.2.e005444.40","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218377","article-title":"Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: \u201cEffect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus\u201d by Chatzidionysiou et al","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:18Z","timestamp":1756929138000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/rmdopen-2025-005444"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005444","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}